Safety and tolerability of switching to bictegravir/emtricitabine/tenofovir alafenamide versus continuing dolutegravir/lamivudine in people living with HIV with neuropsychiatric comorbidities: Week 24 and 48 results from the Management of INSTI-associated Neuropsychiatric Disorders (MIND) clinical trial.

Perez-Valero I, Corona Mata D, Crussells Canales MJ, Velasco Arribas M, Mican Rivera R, Ryan P, Navarrete-Lorite MN, Tiraboschi J, Barrado-Cuchillo J, Molero Bonilla M, Artigues Serra F, Mena de Cea A, de la Fuente Moral S, Perez Stachowski X, Garcia Fraile LJ, Diaz Almidon M, Gil P, Ferreira Tata C, Rivero Juarez A, Rivero A

Open source

DOI: 10.1016/j.ijantimicag.2026.107825
Published: 2026 Aug
Container: International journal of antimicrobial agents
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ijantimicag.2026.107825,
  title = {Safety and tolerability of switching to bictegravir/emtricitabine/tenofovir alafenamide versus continuing dolutegravir/lamivudine in people living with HIV with neuropsychiatric comorbidities: Week 24 and 48 results from the Management of INSTI-associated Neuropsychiatric Disorders (MIND) clinical trial.},
  author = {Perez-Valero I and Corona Mata D and Crussells Canales MJ and Velasco Arribas M and Mican Rivera R and Ryan P and Navarrete-Lorite MN and Tiraboschi J and Barrado-Cuchillo J and Molero Bonilla M and Artigues Serra F and Mena de Cea A and de la Fuente Moral S and Perez Stachowski X and Garcia Fraile LJ and Diaz Almidon M and Gil P and Ferreira Tata C and Rivero Juarez A and Rivero A},
  year = {2026},
  journal = {International journal of antimicrobial agents},
  doi = {10.1016/j.ijantimicag.2026.107825},
  url = {https://doi.org/10.1016/j.ijantimicag.2026.107825}
}

RIS

TY  - JOUR
TI  - Safety and tolerability of switching to bictegravir/emtricitabine/tenofovir alafenamide versus continuing dolutegravir/lamivudine in people living with HIV with neuropsychiatric comorbidities: Week 24 and 48 results from the Management of INSTI-associated Neuropsychiatric Disorders (MIND) clinical trial.
AU  - Perez-Valero I
AU  - Corona Mata D
AU  - Crussells Canales MJ
AU  - Velasco Arribas M
AU  - Mican Rivera R
AU  - Ryan P
AU  - Navarrete-Lorite MN
AU  - Tiraboschi J
AU  - Barrado-Cuchillo J
AU  - Molero Bonilla M
AU  - Artigues Serra F
AU  - Mena de Cea A
AU  - de la Fuente Moral S
AU  - Perez Stachowski X
AU  - Garcia Fraile LJ
AU  - Diaz Almidon M
AU  - Gil P
AU  - Ferreira Tata C
AU  - Rivero Juarez A
AU  - Rivero A
PY  - 2026
JO  - International journal of antimicrobial agents
DO  - 10.1016/j.ijantimicag.2026.107825
UR  - https://doi.org/10.1016/j.ijantimicag.2026.107825
ER  -

APA

I, P., D, C. M., MJ, C. C., M, V. A., R, M. R., P, R., MN, N., J, T., J, B., M, M. B., F, A. S., A, M. D. C., S, D. L. F. M., X, P. S., LJ, G. F., M, D. A., P, G., C, F. T., A, R. J., & A, R. (2026). Safety and tolerability of switching to bictegravir/emtricitabine/tenofovir alafenamide versus continuing dolutegravir/lamivudine in people living with HIV with neuropsychiatric comorbidities: Week 24 and 48 results from the Management of INSTI-associated Neuropsychiatric Disorders (MIND) clinical trial.. International journal of antimicrobial agents. https://doi.org/10.1016/j.ijantimicag.2026.107825

Source records

pubmed · retrieved 2026-09-26T10:43:19.469Z
europe-pmc · retrieved 2026-09-26T10:43:19.494Z